Nurix Therapeutics, Inc. (NRIX) - What Are Analysts Saying About This Stock?

Nurix Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst sentiment is broadly positive: 14 of 15 analysts rate Nurix Therapeutics a buy, versus one sell, producing a “Moderate Buy” consensus and an average 12-month price target of $34.43. Recent target changes were mixed, ranging from Wells Fargo’s cut to $20 to increases by HC Wainwright and Baird to $36.
  • The company reported a large quarterly earnings beat: Nurix posted EPS of $4.73 versus analysts’ expected loss of $0.60, and revenue of $673.06 million versus expectations of $24.35 million.
  • Insiders sold shares recently: Company insiders sold 38,499 shares worth about $893,645 over 90 days; disclosed transactions were conducted under pre-arranged trading plans.
  • Five stocks to consider instead of Nurix Therapeutics.

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have earned an average rating of "Moderate Buy" from the fifteen analysts that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and fourteen have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $34.43.

Several equities research analysts recently issued reports on NRIX shares. UBS Group upped their price target on Nurix Therapeutics from $23.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, July 22nd. HC Wainwright upped their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a "buy" rating in a research note on Friday, October 16th. Wells Fargo & Company reduced their target price on shares of Nurix Therapeutics from $25.00 to $20.00 and set an "overweight" rating for the company in a research note on Wednesday, November 4th. Royal Bank Of Canada lowered their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set an "outperform" rating for the company in a report on Tuesday, October 13th. Finally, Robert W. Baird raised their price target on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an "outperform" rating in a research report on Tuesday, October 13th.

Get Our Latest Research Report on Nurix Therapeutics

Nurix Therapeutics Price Performance

NRIX opened at $14.73 on Tuesday. Nurix Therapeutics has a fifty-two week low of $12.43 and a fifty-two week high of $28.23. The firm has a market capitalization of $1.61 billion, a PE ratio of 6.38 and a beta of 1.80. The company's 50-day moving average is $23.04 and its 200 day moving average is $20.12.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, October 13th. The company reported $4.73 earnings per share for the quarter, beating the consensus estimate of ($0.60) by $5.33. The business had revenue of $673.06 million for the quarter, compared to analysts' expectations of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. As a group, analysts expect that Nurix Therapeutics will post 1.14 EPS for the current year.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $26.80, for a total transaction of $38,913.60. Following the transaction, the insider owned 123,452 shares of the company's stock, valued at $3,308,513.60. This trade represents a 1.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Hans van Houte sold 4,769 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total transaction of $74,539.47. Following the transaction, the chief financial officer directly owned 42,745 shares in the company, valued at approximately $668,104.35. This represents a 10.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 38,499 shares of company stock valued at $893,645. Corporate insiders own 6.70% of the company's stock.

Hedge Funds Weigh In On Nurix Therapeutics

Several institutional investors have recently modified their holdings of NRIX. GAMMA Investing LLC grew its stake in Nurix Therapeutics by 95.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company's stock valued at $30,000 after purchasing an additional 620 shares during the period. Nykredit A S purchased a new stake in Nurix Therapeutics during the second quarter worth about $32,000. Integrated Wealth Concepts LLC bought a new stake in Nurix Therapeutics in the second quarter worth about $33,000. Fifth Third Bancorp raised its position in Nurix Therapeutics by 613.8% in the third quarter. Fifth Third Bancorp now owns 1,556 shares of the company's stock worth $37,000 after acquiring an additional 1,338 shares during the period. Finally, KBC Group NV purchased a new position in Nurix Therapeutics in the first quarter valued at about $34,000.

About Nurix Therapeutics

(Get Free Report)

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company's technology focuses on protein degradation, using the cell's natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.

Recommended Stories

Analyst Recommendations for Nurix Therapeutics (NASDAQ:NRIX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nurix Therapeutics Right Now?

Before you consider Nurix Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nurix Therapeutics wasn't on the list.

While Nurix Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines